ERBB2 and breast cancer: Gene expression signatures are used to classify IDC subtypes of hormone receptor‐positive (estrogen and progesterone receptors), that is, luminal A and B, and hormone receptor‐negative HER2 and basal‐like (Perou et al., 2000; Sorlie et al., 2001) breast cancer subtypes.